2
New Label-Free Imaging Tracks Cancer Treatment in Single Cells
mehr
Storys zum Thema Krebs
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
New York and North Chicago, Ill. (ots/PRNewswire) - - ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an ...
mehrFraunhofer-Institut für Produktionstechnologie IPT
Transforming personalized medicine with AI-driven CAR-T manufacturing: Automated CAR-T cell production platform is ready for production
mehrLess than 30 days left to apply – don’t miss your chance
Ein DokumentmehrASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
Petach Tikva, Israel (ots/PRNewswire) - ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential ...
mehrIsotopia and Cardirad Announce Launch of Isoprotrace® in Sweden and Denmark, Expanding Access to Advanced Prostate Cancer Imaging
Petah Tikva, Israel (ots/PRNewswire) - Isotopia Molecular Imaging, in partnership with Cardirad , proudly announces the launch of Isoprotrace®—an advanced Gallium-68 Gozetotide preparation kit for prostate cancer imaging—in Sweden and Denmark. The introduction of Isoprotrace® into these Nordic markets marks a ...
mehr
NeutroFlow: Leading European Medical Consortium Awarded €2.5 Million Grant from EIC Transition Programme to Advance Predictive Biomarker Development for Immunotherapy Response
Heidelberg, Germany, Milan, Seville, Spain and Binyamina, Israel (ots/PRNewswire) - A European-led consortium comprising Heidelberg University Hospital (UKHD), the European Institute of Oncology (IEO), Virgen Macarena University Hospital, and OncoHost today announced that it has been awarded a €2.5 million grant ...
mehrAcousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and ...
mehrHelmholtz Launches Task Force to Strengthen Prevention Research
mehrcanSERV Open Call relaunches: Apply now for Free Access to Cutting-Edge Cancer Research Services
Ein DokumentmehrEngineering Smart Delivery for Gene Editors
mehrTOOsonix Partners with MikronMed to Introduce Innovative Dermatological Therapy in the Nordic Region
Copenhagen, Denmark (ots/PRNewswire) - A groundbreaking dermatological alliance will bring innovative dermatological treatment to the 27 million residents of the Nordic Region, offering rapid and efficient treatment for the most common skin cancer and various skin conditions - often completed in under 90 seconds. ...
mehr
Kinectrics and Isotopia Enter Agreement for Supply of Gadolinium-160 (Gd-160) to Support Production of Terbium-161 (Tb-161) for Advanced Radiotherapeutics
Toronto (ots/PRNewswire) - Kinectrics and Isotopia have announced a groundbreaking agreement under which Kinectrics will provide Isotopia with a reliable supply of Gadolinium-160 (Gd-160). This critical isotope will enable Isotopia's production of Terbium-161 (Tb-161), a medical isotope showing great promise and ...
mehrNorgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in ...
mehrTechnische Universität München
Complex pancreatic tumor organoids as foundation for new treatment strategies
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Foundation for new cancer treatment strategies Organoids represent the complex cell landscape of pancreatic cancer - Tumors are composed of cancer cells with a variety of different characteristics. - This contributes significantly to the complexity of pancreatic cancer and makes the disease difficult to treat. - For the ...
mehrReminder: canSERV Call for Service Provision "Training the Next Generation of Cancer Researchers"
Ein DokumentmehrLast Call for canSERV Third Open Call Funding
Ein DokumentmehrPress Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...
mehr
Launch of canSERV Call for Service Provision – "Training the Next Generation of Cancer Researchers"
Ein DokumentmehrLaunch of canSERV Call for Service Provision, "Training the Next Generation of Cancer Researchers"
Ein Dokumentmehr- 2
Record financing rounds at the Munich biotech hub
Ein Dokumentmehr canSERV relaunches Open Call for Service Provision
Ein DokumentmehrAcousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August ...
mehrcanSERV to Accelerate Your Cancer Research - 2 Calls for Service Provision Open
2 Dokumentemehr
Press release: Alvotech and STADA add to strategic alliance through denosumab partnership
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
Ein DokumentmehrPress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
Ein DokumentmehrcanSERV invites applications for "Revolutionising Cancer Patient Care"
Ein Dokumentmehr- 3
canSERV invites applications for "Revolutionising Cancer Patient Care"
Ein Dokumentmehr LAST CHANCE: canSERV Second Open Call for Cancer Research Service Provision
Ein Dokumentmehr- 3
canSERV Initiative: EU Consortium Launches Groundbreaking Call to Accelerate Cancer Research
Ein Dokumentmehr
1234Nächste